In search of a selective antiviral chemotherapy

Clinical Microbiology Reviews

Volumn 10, Issue 4, 1997, Pages 674-693

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANTIVIRUS AGENT; DEOXYURIDINE; FAMCICLOVIR; GANCICLOVIR; IDOXURIDINE; PENCICLOVIR; SORIVUDINE; TRIFLURIDINE; VALACICLOVIR; VIDARABINE;

ANTIVIRAL ACTIVITY; CHEMICAL STRUCTURE; DNA VIRUS; HERPES VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RETROVIRUS; REVIEW;

ADENOVIRIDAE; DNA VIRUSES; HEPADNAVIRIDAE; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 3; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; PAPILLOMAVIRUS; POLYOMAVIRUS; POXVIRIDAE; UNIDENTIFIED RETROVIRUS;

EID: 0030708683     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.10.4.674-693.1997     Document Type: Review

References (194)

1. Aduma, P., M. C. Connelly, R. V. Srinivas, and A. Fridland. 1995. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol. Pharmacol. 47:816-822.
2. Ahgren, C., K. Backro, F. W. Bell, A. S. Cantrell, M. Clemens, J. M. Colacino, J. B. Deeter, J. A. Engelhardt, M. Hogberg, S. R. Jaskunas, N. G. Johansson, C. L. Jordan, J. S. Kasher, M. D. Kinnick, P. Lind, C. Lopez, J. M. Morin, Jr., M. A. Muesing, R. Noreen, B. Öberg, C. J. Paget, J. A. Palkowitz, C. A. Parrish, P. Pranc, M. K. Rippy, C. Rydergard, C. Sahlberg, S. Swanson, R. J. Ternansky, T. Unge, R. T. Vasileff, L. Vrang, S. J. West, H. Zhang, and X.-X. Zhou. 1995. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1329-1335.
3. Allaudeen, H. S., J. W. Kozarich, J. R. Bertino, and E. De Clercq. 1981. On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2′-deoxyuridine. Proc. Natl. Acad. Sci. USA 78:2698-2702.
4. Andrei, G., R. Snoeck, D. Reymen, C. Liesnard, P. Goubau, J. Desmyter, and E. De Clercq. 1995. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur. J. Clin. Microbiol. Infect. Dis. 14:318-328.
5. Ayisi, N. K., E. De Clercq, R. A. Wall, H. Hughes, and S. L. Sacks. 1984. Metabolic fate of (E)-5-(2-bromovinyl)-2′-deoxyuridine in herpes simplex virus-and mock-infected cells. Antimicrob. Agents Chemother. 26:762-765.
6. Baba, M., H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C.-F. Perno, R. T. Walker, and T. Miyasaka. 1989. High specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun 165: 1375-1381.
7. Baba, M., E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, H. Nakashima, S. Mori, S. Shigeta, R. T. Walker, and T. Miyasaka. 1991. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 88:2356-2360.
8. Baba, M., E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, R. T. Walker, S. Mori, M. Ito, S. Shigeta, and T. Miyasaka. 1991. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 39:805-810.
9. Baba, M., S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R. T. Walker, and E. De Clercq. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother 38:688-692.
10. Bader, J. P., J. B. McMahon, R. J. Schultz, V. L. Narayanan, J. B. Pierce, W. A. Harrison, O. S. Weislow, C. F. Midelfort, S. F. Stinson, and M. R. Boyd. 1991. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. USA 88:6740-6744.
11. Balzarini, J. and E. De Clercq. 1991. 5-Phosphoribosyl 1-pyrophosphate synthetase converts the acyclic nucleoside phosphonates 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 9-(2-phosphonylmethoxyethyl)adenine directly to their antivirally active diphosphate derivatives. J. Biol. Chem. 266:8686-8689.
12. Balzarini, J., E. De Clercq, D. Ayusawa, and T. Seno. 1985. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett. 185:95-100.
13. Balzarini, J., E. De Clercq, A. Verbruggen, D. Ayusawa, and T. Seno. 1985. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxvuridine derivatives for murinc mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene. Mol. Pharmacol 28:581-587.
14. Balzarini, J., E. De Clercq, A. Verbruggen, D. Ayusawa, K. Shimizu, and T. Seno. 1987. Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene. Mol. Pharmacol. 32:410-416.
15. Balzarini, J., L. Naesens, P. Herdewijn, I. Rosenberg, A. Holý, R. Pauwels, M. Baba, D. G. Johns, and E. De Clercq. 1989. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. USA 86:332-336.
16. Balzarini, J., R. Bernaerts, A. Verbruggen, and E. De Clercq. 1990. Role of the incorporation of (E)-5-(2-iodovinyl)-2′-deoxyuridine and its carbocyclic analogue into DNA of herpes simplex virus type 1-infected cells in the antiviral effects of these compounds. Mol. Pharmacol. 37:402-407.
17. Balzarini, J., Z. Hao, P. Herdewijn, D. G. Johns, and E. De Clercq. 1991. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88:1499-1503.
18. Balzarini, J., A. Holý, J. Jindrich, H. Dvorakova, Z. Hao, R. Snoeck, P. Herdewijn, D. G. Johns, and E. De Clercq. 1991. 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc. Natl. Acad. Sci. USA 88: 4961-4965.
19. Balzarini, J., L. Naesens, J. Slachmuylders, H. Niphuis, I. Rosenberg, A. Holý, H. Schellekens, and E. De Clercq. 1991. 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 5:21-28.
20. Balzarini, J., M.-J. Pérez-Pérez, A. San-Félix, D. Schols, C.-F. Perno, A.-M. Vandamme, M.-J. Camarasa, and E. De Clercq. 1992. 2′,5′-Bis-O-(tertbutyldimethylsilyl)-3′-spiro-5″- (4″-amino-1″,2″-oxathiole-2″,2″-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. USA 89:4392-4396.
21. Balzarini, J., C. Bohman, and E. De Clercq. 1993. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J. Biol. Chem. 268:6332-6337.
22. Balzarini, J., A. Holý, J. Jindrich, L. Naesens, R. Snoeck, D. Schols, and E. De Clercq. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother 37: 332-338.
23. Balzarini, J., A. Karlsson, M.-J. Pérez-Pérez, M.-J. Camarasa, and E. De Clercq. 1993. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196:576-585.
24. Balzarini, J., C. Bohman, R. T. Walker, and E. De Clercq. 1994. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol. Pharmacol. 45:1253-1258.
25. Balzarini, J., A. Karlsson, C. Meichsner, A. Paessens, G. Riess, E. De Clercq, and J.-P. Kleim. 1994. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 68:7986-7992.
26. Balzarini, J., A. Karlsson, V. V. Sardana, E. A. Emini, M.-J. Camarasa, and E. De Clercq. 1994. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C → C1S1I)RT HIV-1 mutants. Proc. Natl. Acad. Sci. USA 91:6599-6603.
27. Balzarini, J., M. Baba, and E. De Clercq. 1995. Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains. Antimicrob. Agents Chemother. 39:998-1002.
28. Balzarini, J., W. G. Brouwer, E. E. Felauer, E. De Clercq, and A. Karlsson. 1995. Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains. Antiviral Res. 27:219-236.
29. Balzarini, J., H. Jonckheere, W. A. Harrison, D. C. Dao, J. Anné, E. De Clercq, and A. Karlsson. 1995. Oxathiin carboxanilide derivatives: a class of non-nucleoside HIV-1-specific reverse transcriptase inhibitors (NNRTIs) that are active against mutant HIV-1 strains resistant to other NNRTIs. Antiviral Chem. Chemother. 6:169-178.
30. Balzarini, J., M.-J. Pérez-Pérez, S. Vélazquez, A. San-Félix, M.-J. Camarasa, E. De Clercq, and A. Karlsson. 1995. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives). Proc. Natl. Acad. Sci. USA 92:5470-5474.
31. Balzarini, J., W. G. Brouwer, D. C. Dao, E. M. Osika, and E. De Clercq. 1996. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1454-1466.
32. Balzarini, J., H. Pelemans, S. Aquaro, C.-F. Perno, M. Witvrouw, D. Schols, E. De Clercq, and A. Karlsson. 1996. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Mol. Pharmacol. 50:394-401.
33. Balzarini, J., H. Pelemans, A. Karlsson, E. De Clercq, and J.-P. Kleim. 1996. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 93:13152-13157.
34. Balzarini, J., H. Pelemans, M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, E. De Clercq, and A. Karlsson. 1996. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine. Mol. Pharmacol. 49:882-890.
35. 34a. Balzarini, J., et al. Unpublished data.
36. Barditch-Crovo, P. A., J. Toole, H. Burgee, M. Wachsman, D. Ebeling, K. C. Cundy, H. S. Jaffe, and P. S. Lietman. 1995. A randomized, double-blind, placebo-controlled phase I/II evaluation of 9-[2-(bispivaloyloxy-methyl)phosphonylmethoxy]adenine (bis-POM PMEA), an orally bioavailable prodrug of the anti-HIV nucleotide, PMEA. Abstracts of the Eighth International Conference on Antiviral Research. Antiviral Res. 26:A229. (Abstract.)
37. Bauer, D. J. 1955. The antiviral and synergistic actions of isatin thiosemicarbazone and certain phenoxypyrimidines in vaccinia infection in mice. Br. J. Exp. Pathol. 36:105-114.
38. Bauer, D. J., L. St. Vincent, C. H. Kempe, and A. W. Downie. 1963. Prophylactic treatment of smallpox contacts with N-methylisatin β-thiosemicarbazone. Lancet ii:494-496.
39. Benoit, Y., G. Laureys, M.-J. Delbeke, and E. De Clercq. 1985. Oral BVDU treatment of varicella and zoster in children with cancer. Eur. J. Pediatr. 143:198-202.
40. Bischofberger, N., M. J. M. Hitchcock, M. S. Chen, D. B. Barkhimer, K. C. Cundy, K. M. Kent, S. A. Lacy, W. A. Lee, Z.-H. Li, D. B. Mendel, D. F. Smee, and J. L. Smith. 1994. 1-[((S)-2-Hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine, an intracellular prodrug for (5)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob. Agents Chemother. 38:2387-2391.
41. Bischofberger, N., C.-C. Tsai, K. E. Follis, A. Sabo, R. F. Grant, T. W. Beck, P. J. Dailey, and R. Black. 1996. Antiviral efficacy of PMPA in macaques chronically infected with SIV. Antivir. Res. 30:A42. (Abstract.)
42. Bohman, C., J. Balzarini, P. Wigerinck, A. Van Aerschot, P. Herdewijn, and E. De Clercq. 1994. Mechanism of cytostatic action of novel 5-(thien-2-yl)-and 5-(furan-2-yl)-substituted pyrimidine nucleoside analogues against tumor cells transfected by the thymidine kinase gene of herpes simplex virus. J. Biol. Chem. 269:8036-8043.
43. Cao, Y., L. Qin, L. Zhang, J. Safrit, and D. D. Ho. 1995. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332:201-208.
44. Cherrington, J. M., S. J. Allen, B. H. McKee, and M. S. Chen. 1994. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases β and γ. Biochem. Pharmacol. 48:1986-1988.
45. Cherrington, J. M., S. J. W. Allen, N. Bischofberger, and M. S. Chen. 1995. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl)-adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β and γ. Antiviral Chem. Chemother. 6:217-221.
46. Cihlár, T., I. Votruba, K. Horská, R. Liboska, I. Rosenberg, and A. Holý. 1992. Metabolism of 1-(5)-(3-hydroxy-2-phosphonomethoxypropyl)cytosine (HPMPC) in human embryonic lung cells. Collect. Czech. Chem. Commun. 57:661-672.
47. Connelly, M. C., B. L. Robbins, and A. Fridland. 1993. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells. Biochem. Pharmacol. 46: 1053-1057.
48. Crooks, R. J., and A. Murray. 1994. Valaciclovir - a review of a promising new antiherpes agent. Antiviral Chem. Chemother. 5(Suppl. 1):31-37.
49. Cundy, K. C., A. M. Bidgood, G. Lynch, J.-P. Shaw, L. Griffin, and W. A. Lee. 1996. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab. Dispos. 24:745-752.
50. Cundy, K. C., Z.-H. Li, M. J. M. Hitchcock, and W. A. Lee. 1996. Pharmacokinetics of cidofovir in monkeys. Evidence for a prolonged elimination phase representing phosphorylated drug. Drug Metab. Dispos. 24:738-744.
51. D'Aquila, R. T., M. D. Hughes, V. A. Johnson, M. A. Fischl, J.-P. Sommadossi, S.-H. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu, M. S. Hirsch, and The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. 1996. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann. Intern. Med. 124:1019-1030.
52. Davey, R. T., Jr., D. G. Chaitt, G. F. Reed, W. W. Freimuth, B. R. Herpin, J. A. Metcalf, P. S. Eastman, J. Falloon, J. A. Kovacs, M. A. Polis, R. E. Walker, H. Masur, J. Boyle, S. Colemans, S. R. Cox, L. Wathen, C. L. Daenzer, and H. C. Lane. 1996. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40:1657-1664.
53. Davies, W. L., R. R. Grunert, R. F. Haff, J. W. McGahen, E. M. Neumayer, M. Paulshock, J. C. Watts, T. R. Wood, E. C. Hermann, and C. E. Hoffmann. 1964. Antiviral activity of 1-adamantanamine (amantadine). Science 144:862-863.
54. Debyser, Z., R. Pauwels, K. Andries, J. Desmyter, M. Kukla, P. A. J. Janssen, and E. De Clercq. 1991. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione derivatives. Proc. Natl. Acad. Sci. USA 88:1451-1455.
55. De Clercq, E. 1982. Selective antiherpes agents. Trends Pharmacol. Sci. 3:492-495.
56. De Clercq, E. D. A. 1982. Interferon. A molecule for all seasons, p. 87-138. In L. C. Olson (ed.), Virus infections. Modern concepts and status. Marcel Dekker, Inc., New York, N.Y.
57. De Clercq, E. 1984. Topical treatment of cutaneous herpes simplex virus infection in hairless mice with (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. Antimicrob. Agents Chemother. 26:155-159.
58. De Clercq, E. 1984. The antiviral spectrum of (E)-5-(2-bromovinyl)-2'-deoxyuridine. J. Antimicrob. Chemother. 14(Suppl. A):85-95.
59. De Clercq, E. 1985. Synthetic pyrimidine nucleoside analogues, p. 57-99. In M. R. Harnden (ed.). Approaches to antiviral agents. Macmillan, London, United Kingdom.
60. De Clercq, E. 1987. S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents. Biochem. Pharmacol. 36:2567-2575.
61. De Clercq, E. 1991. Broad-spectrum anti-DNA virus and anti-retrovirus activity of phosphonylmethoxyalkylpurines and -pyrimidines. Biochem. Pharmacol. 42:963-972.
62. De Clercq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
63. De Clercq, E. 1993. Therapeutic potential of HPMPC as an antiviral drug. Rev. Med. Virol. 3:85-96.
64. De Clercq, E. 1993. Antivirals for the treatment of herpesvirus infections. J. Antimicrob. Chemother. 32(Suppl. A):121-132.
65. De Clercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-169.
66. De Clercq, E. 1995. Trends in the development of new antiviral agents for the chemotherapy of infections caused by herpesviruses and retroviruses. Rev. Med. Virol. 5:149-164.
67. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:200-239.
68. De Clercq, E. 1995. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 38:2491-2517.
69. De Clercq, E. 1996. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Rev. Med. Virol. 6:97-117.
70. De Clercq, E. 1996. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development. Med. Res. Rev. 16:125-157.
71. De Clercq, E. 1996. Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections. Int. J. Antimicrob. Agents 7:193-202.
72. 70a.De Clercq, E. Unpublished data.
73. De Clercq, E., and A. Holý. 1991. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob. Agents Chemother. 35:701-706.
74. De Clercq, E., and J. Balzarini. 1995. Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS. Farmaco 50:735-747.
75. De Clercq, E., J. Descamps, P. De Somer, and A. Holý. 1978. (S)-9-(2,3-Dihydroxypropyl)adenine: an aliphatic nucleoside analog with broad-spectrum antiviral activity. Science 200:563-565.
76. De Clercq, E., J. Descamps, P. De Somer, P. J. Barr, A. S. Jones, and R. T. Walker. 1979. (E)-5-(2-Bromovinyl)-2′-deoxyuridine: a potent and selective anti-herpes agent. Proc. Natl. Acad. Sci. USA 76:2947-2951.
77. De Clercq, E., A. Holý, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature 323:464-467.
78. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holý. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res. 8:261-272.
79. De Clercq, E., M. Cools, J. Balzarini, V. E. Marquez, D. R. Borcherding, R. T. Borchardt, J. C. Drach, S. Kitaoka, and T. Konno. 1989. Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5′-nor derivatives. Antimicrob. Agents Chemother. 33:1291-1297.
80. De Clercq, E., A. Holý, and I. Rosenberg. 1989. Efficacy of phosphonylmethoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob. Agents Chemother. 33:185-191.
81. Descamps, J., and E. De Clercq. 1981. Specific phosphorylation of E-5-(2-iodovinyl)-2′-deoxyuridine by herpes simplex virus-infected cells. J. Biol. Chem. 256:5973-5976.
82. De Wit, S., P. Hermans, B. Sommereijns, E. O'Doherty, R. Westenborghs, V. Van De Velde, G. F. M. J. Cauwenbergh, and N. Clumeck. 1992. Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion. Antimicrob. Agents Chemother. 36:2661-2663.
83. Ding, J., K. Das, H. Moereels, L. Koymans, K. Andries, P. A. J. Janssen, S. H. Hughes, and E. Arnold. 1995. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 2:407-415.
84. Ding, J., K. Das, C. Tantillo, W. Zhang, A. D. Clark, Jr., S. Jessen, X. Lu, Y. Hsiou, A. Jacobo-Molina, K. Andries, R. Pauwels, H. Moereels, L. Koymans, P. A. J. Janssen, R. H. Smith, Jr., M. Kroeger Koepke, C. J. Michejda, S. H. Hughes, and E. Arnold. 1995. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 3:365-379.
85. Domagk, G., R. Behnisch, F. Mietzch, and H. Schmidt. 1946. Über eine neue, gegen Tuberkelbazillen in vitro wirksame Verbindungsklasse. Naturwissenschaften 10:315.
86. Dueweke, T. J., S. M. Poppe, D. L. Romero, S. M. Swaney, A. G. So, K. M. Downey, I. W. Althaus, F. Reusser, M. Busso, L. Resnick, D. L. Mayers, J. Lane, P. A. Aristoff, R. C. Thomas, and W. G. Tarpley. 1993. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 37:1127-1131.
87. Egberink, H., M. Borst, H. Niphuis, J. Balzarini, H. Neu, H. Schellekens, E. De Clercq, M. Horzinek, and M. Koolen. 1990. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc. Natl. Acad. Sci. USA 87:3087-3091.
88. Elion, G. B., P. A. Furman, J. A. Fyfe, P. de Miranda, L. Beauchamp, and H. J. Schaeffer. 1977. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc. Natl. Acad. Sci. USA 74:5716-5720.
89. Faulds, D., and R. N. Brogden. 1992. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs 44:94-116.
90. Field, H. J. 1996. Famciclovir - origins, progress and prospects. Exp. Opin. Invest. Drugs 5:925-938.
91. Flores-Aguilar, M., J.-S. Huang, C. A. Wiley, E. De Clercq, C. Vuong, G. Bergeron-Lynn, B. Chandler, D. Munguia, and W. R. Freeman. 1994. Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. J. Infect. Dis. 169:642-647.
92. Fyfe, J. A. 1982. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol. Pharmacol. 21:432-437.
93. Fyfe, J. A., P. M. Keller, P. A. Furman, R. L. Miller, and G. B. Elion. 1978. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 253: 8721-8727.
94. Goldman, M. E., J. H. Nunberg, J. A. O'Brien, J. C. Quintero, W. A. Schleif, K. F. Freund, S. L. Gaul, W. S. Saari, J. S. Wai, J. M. Hoffman, P. S. Anderson, D. J. Hupe, E. A. Emini, and A. M. Stern. 1991. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88:6863-6867.
95. Hamre, D., K. A. Brownlee, and R. Donovick. 1951. Studies on the chemotherapy of vaccinia virus. II. The activity of some thiosemicarbazones. J. Immunol. 67:305-312.
96. Havlir, D., S. H. Cheeseman, M. McLaughlin, R. Murphy, A. Erice, S. A. Spector, T. C. Greenough, J. L. Sullivan, D. Hall, M. Myers, M. Lamson, and D. D. Richman. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infec-tion. J. Infect. Dis. 171:537-545.
97. Heijtink, R. A., G. A. De Wilde, J. Kruining, L. Berk, J. Balzarini, E. De Clercq, A. Holý, and S. W. Schalm. 1993. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 21:141-153.
98. Heijtink, R. A., J. Kruining, G. A. De Wilde, J. Balzarini, E. De Clercq, and S. W. Schalm. 1994. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob. Agents Chemother. 38:2180-2182.
99. Herdewijn, P., E. De Clercq, J. Balzarini, and H. Vanderhaeghe. 1985. Synthesis and antiviral activity of the carbocyclic analogues of (E)-5-(2-halovinyl)-2′-deoxyuridines and (E)-5-(2-halovinyl)-2′-deoxycytidines. J. Med. Chem. 28:550-555.
100. Hitchcock, M. J. M., H. S. Jaffe, J. C. Martin, and R. J. Stagg. 1996. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem. Chemother. 7:115-127.
101. Ho, D. D. 1996. Viral counts count in HIV infection. Science 272:1124-1125.
102. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
103. Ho, H.-T., L. Woods, J. J. Bronson, H. De Boeck, J. C. Martin, and M. J. M. Hitchcock. 1992. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol. Pharmacol. 41:197-202.
104. Kaufman, H. E. 1962. Clinical cure of herpes simplex keratitis by 5-iodo-2′-deoxyuridine. Proc. Soc. Exp. Biol. Med. 109:251-252.
105. Kaufman, H. E., and C. Heidelberger. 1964. Therapeutic antiviral action of 5-trifluoromethyl-2′-deoxyuridine in herpes simplex keratitis. Science 145: 585-586.
106. Kaufman, H. E., E. Martola, and C. Dohlman. 1962. Use of 5-iodo-2′-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch. Ophthalmol. 68:235-239.
107. Kirsch, L. S., J. F. Arevalo, E. Chavez de la Paz, D. Munguia, E. De Clercq, and W. R. Freeman. 1995. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 102:533-543.
108. Kirsch, L. S., J. F. Arevalo, E. De Clercq, E. Chavez de la Paz, D. Munguia, R. Garcia, and W. R. Freeman. 1995. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 119:466-476.
109. Kit, S., H. Ichimura, and E. De Clercq. 1987. Differential metabolism of (E)-5-(2-iodovinyl)-2′-deoxyuridine (IVDU) by equine herpesvirus type 1-and herpes simplex virus-infected cells. Antiviral Res. 8:41-51.
110. Kleim, J.-P., R. Bender, U.-M. Billhardt, C. Meichsner, G. Riess, M. Rösner, I. Winkler, and A. Paessens. 1993. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37:1659-1664.
111. Kramata, P., I. Votruba, B. Otová, and A. Holý. 1996. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases α, β, and ε. Mol. Pharmacol. 49:1005-1011.
112. Kroeger Smith, M. B., C. A. Rouzer, L. A. Taneyhill, N. A. Smith, S. H. Hughes, P. L. Boyer, P. A. J. Janssen, H. Moereels, L. Koymans, E. Arnold, J. Ding, K. Das, W. Zhang, C. J. Michejda, and R. H. Smith, Jr. 1995. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity. Protein Sci. 4:2203-2222.
113. Lalezari, J. P., W. L. Drew, E. Glutzer, D. Miner, S. Safrin, W. F. Owen, Jr., J. M. Davidson, P. E. Fisher, and H. S. Jaffe. 1994. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J. Infect. Dis. 170:570-572.
114. Lalezari, J. P., W. L. Drew, E. Glutzer, C. James, D. Miner, J. Flaherty, P. E. Fisher, K. Cundy, J. Hannigan, J. C. Martin, and H. S. Jaffe. 1995. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis. 171:788-796.
115. Lalezari, J., H. S. Jaffe, T. Schacker, J. Feinberg, S. Lee, J. Gathe, F. Kramer, H. Kessler, T. Cheung, W. L. Drew, B. McGuire, and S. Safrin. 1996. A randomized, double-blinded, placebo-controlled study of cidofovir topical gel for acyclovir-resistant herpes simplex virus infections in patients with AIDS. In Abstracts of the Third National Conference on AIDS, Washington, D.C., 28 to 31 January 1996.
116. Lalezari, J. P., R. Stagg, B. Kuppermann, G. Holland, F. Kramer, D. Ives, M. Youle, M. Robinson, W. L. Drew, and H. S. Jaffe. 1997. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann. Intern. Med. 126:257-263.
117. Langtry, H. D., and D. M. Campoli-Richards. 1989. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 37:408-450.
118. Larin, N. M. 1967. Cardinal problems in search for antiviral drugs. Chemotherapia 12:201-214.
119. Lea, A. P., and D. Faulds. Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 51:846-864.
120. Lin, J.-C-, M. C. Smith, Y.-C. Cheng, and J. S. Pagano. 1983. Epstein-Barr virus: inhibition of replication by three new drugs. Science 221:578-579.
121. Machida, H., S. Sakata, A. Kuninaka, and H. Yoshino. 1981. Antiherpesviral and anticellular effects of 1-β-D-arabinofuranosyl-E-5-(2-halogenovinyl)uracils. Antimicrob. Agents Chemother. 20:47-52.
122. Mancini, W. R., E. De Clercq, and W. H. Prusoff. 1983. The relationship between incorporation of E-5-(2-bromovinyl)-2′-deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity. J. Biol. Chem. 258:792-795.
123. Markham, A., and D. Faulds. 1994. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 48:455-484.
124. Maudgal, P. C. and E. De Clercq. 1991. Bromovinyldeoxyuridine treatment of herpetic keratitis clinically resistant to other antiviral agents. Curr. Eye Res. 10(Suppl.):193-199.
125. Mayers, D. L., J. A. Mikovits, B. Joshi, I. K. Hewlett, J. S. Estrada, A. D. Wolfe, G. E. Garcia, B. P. Doctor, D. S. Burke, R. K. Gordon, J. R. Lane, and P. K. Chiang. 1995. Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: increased potency against 3′-azido-3′-deoxythymidine-resistant HIV-1 strains. Proc. Natl. Acad. Sci. USA 92: 215-219.
126. Mellors, J. W., C. R. J. Rinaldo, P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantify of virus in plasma. Science 272:1167-1170.
127. Merluzzi, V. J., K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. Wu, C.-K. Shih, K. Eckner, S. Hattox, J. Adams, A. S. Rosenthal, R. Faanes, R. J. Eckner, R. A. Koup, and J. L. Sullivan. 1990. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
128. Merta, A., I. Votruba, J. Jindrich, A. Holý, T. Cihlár, I. Rosenberg, M. Otmar, and T. Y. Herve. 1992. Phosphorylation of 9-(2-phosphonomethoxyethyl)adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine by AMP (dAMP) kinase from L1210 cells. Biochem. Pharmacol. 44:2067-2077.
129. Miller, C., Z. Rosenberg, and N. Bischofberger. 1996. Use of topical PMPA to prevent vaginal transmission of SIV. Ninth International Conference on Antiviral Research, Urabandai, Fukushima, Japan, 19 to 24 May 1996.
130. Miyasaka, T., H. Tanaka, M. Baba, H. Hayakawa, R. T. Walker, J. Balzarini, and E. De Clercq. 1989. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32:2507-2509.
131. Moyle, G., and B. Gazzard. 1996. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 51:701-712.
132. Naesens, L., J. Balzarini, and E. De Clercq. 1994. Therapeutic potential of PMEA as an antiviral drug. Rev. Med. Virol. 4:147-159.
133. Naesens, L., J. Balzarini, N. Bischofberger, and E. De Clercq. 1996. Anti-retroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 40:22-28.
134. Neyts, J., R. Snoeck, D. Schols, J. Balzarini, and E. De Clercq. 1990. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 179:41-50.
135. Neyts, J., H. Sobis, R. Snoeck, M. Vandeputte, and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur. J. Clin. Microbiol. Infect. Dis. 12:269-279.
136. Nitschko, H., H. Lindhofer, H. Schätzl, J. Eberle, G. Deby, B. Kranz, and K. von der Helm. 1994. Long-term treatment of HIV-infected MT-4 cells in culture with HIV proteinase inhibitor Ro 31-8959 leads to complete cure of infection. Antiviral Chem. Chemother. 5:236-242.
137. Noble, S., and D. Faulds. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
138. Öberg, B. 1983. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 19:387-415.
139. O'Brien, W. A., P. M. Hartigan, D. Martin, J. Esinhart, A. Hill, S. Benoit, M. Rubin, M. S. Simberkoff, J. D. Hamilton, and The Veterans Affairs Cooperative Study Group on AIDS. 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426-431.
140. Okamoto, M., M. Makino, K. Yamada, K. Nakade, S. Yuasa, and M. Baba. 1996. Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells. Antiviral Res. 31:69-77.
141. Pantaleo, G., S. Menzo, M. Vaccarezza, C. Graziosi, O. J. Cohen, J. F. Demarest, D. Montefiori, J. M. Orenstein, C. Fox, L. K. Schrager, J. B. Margolick, S. Buchbinder, J. V. Giorgi, and A. S. Fauci. 1995. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332:209-216.
142. Pauwels, R., K. Andries, J. Desmyter, D. Schols, M. J. Kukla, H. J. Breslin, A. Raeymaeckers, J. Van Gelder, R. Woestenborghs, J. Heykants, K. Schellekens, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343:470-474.
143. Pauwels, R., K. Andries, Z. Debyser, P. Van Daele, D. Schols, P. Stoffels, K. De Vreese, R. Woestenborghs, A.-M. Vandamme, C. G. M. Janssen, J. Anné, G. Cauwenbergh, J. Desmyter, J. Heykants, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1993. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:1711-1715.
144. Pauwels, R., K. Andries, Z. Debyser, M. J. Kukla, D. Schols, H. J. Breslin, R. Woestenborghs, J. Desmyter, M. A. C. Janssen, E. De Clercq, and P. A. J. Janssen. 1994. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrob. Agents Chemother. 38:2863-2870.
145. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
146. Privat de Garilhe, M., and J. De Rudder. 1964. Effet de deux nucléosides de l'arabinose sur la multiplication des virus de l'herpès et de la vaccine en culture cellulaire. C. R. Acad. Sci. 259:2725-2728.
147. Prusoff, W. H. 1959. Synthesis and biological activities of iododeoxyuridine, an analogue of thymidine. Biochim. Biophys. Acta 32:295-296.
148. Ren, J., R. Esnouf, E. Garman, D. Somers, C. Ross, I. Kirby, J. Keeling, G. Darby, Y. Jones, D. Stuart, and D. Stammers. 1995. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2:293-302.
149. Ren, J., R. Esnouf, A. Hopkins, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 3:915-926.
150. Reymen, D., L. Naesens, J. Balzarini, A. Holý, H. Dvoráková, and E. De Clercq. 1995. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6. Antiviral Res. 28:343-357.
151. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
152. Robbins, B. L., J. Greenhaw, M. C. Connelly, and A. Fridland. 1995. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonyl-methoxyethyl)adenine in human lymphoid cells. Antimicrob. Agents Chemother. 39:2304-2308.
153. Romero, D. L., M. Busso, C.-K. Tan, F. Reusser, J. R. Palmer, S. M. Poppe, P. A. Aristoff, K. M. Downey, A. G. So, L. Resnick, and W. G. Tarpley. 1991. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. USA 88:8806-8810.
154. Saag, M. S., E. A. Emini, O. L. Laskin, J. Douglas, W. I. Lapidus, W. A. Schleif, R. J. Whitley, C. Hildebrand, V. W. Byrnes, J. C. Kappes, K. W. Anderson, F. E. Massari, G. M. Shaw, and the L-697,661 Working Group. 1993. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N. Engl. J. Med. 329:1065-1072.
155. Sacks, S. L., J. J. Sasadeusz, A. Hughes, S. Shafran, F. Diaz-Mitoma, S. Trottier, G. Sibbald, B. W. McGuire, J. Rudy, and H. S. Jaffe. 1996. Cidofovir topical gel single-dose therapy for recurrent genital herpes in the immunocompetent host: results of a Canadian multicenter, randomized, double-blind, placebo-controlled dose-escalation pilot study. Ninth International Conference on Antiviral Research, Urabandai, Fukushima, Japan, 19 to 24 May 1996.
156. Schabel, F. M., Jr. 1968. The antiviral activity of 9-β-D-arabinofuranosyladenine (ara-A). Chemotherapy 13:321-338.
157. Schabel, F. M., Jr., and J. A. Montgomery. 1982. Purines and pyrimidines, p. 231-263. In D. J. Bauer (ed.), Chemotherapy of virus diseases, vol. I. Pergamon Press, Oxford, United Kingdom.
158. Schaeffer, H. J., L. Beauchamp, P. de Miranda, G. B. Elion, D. J. Bauer, and P. Collins. 1978. 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes group. Nature 272:583-585.
159. Sham, H. L., and X. Chen. HIV protease inhibitors in early development. Exp. Opin. Invest. Drugs 5:977-983.
160. Shigeta, S., T. Yokota, T. Iwabuchi, M. Baba, K. Konno, M. Ogata, and E. De Clercq. 1983. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J. Infect. Dis. 147:576-584.
161. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
162. Snoeck, R., T. Sakuma, E. De Clercq, I. Rosenberg, and A. Holý. 1988. (S)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 32:1839-1844.
163. Snoeck, R., G. Andrei, E. De Clercq, M. Gérard, N. Clumeck, G. Tricot, and C. Sadzot-Delvaux. 1993. A new topical treatment for resistant herpes simplex infections. N. Engl. J. Med. 329:968-969.
164. Snoeck, R., G. Andrei, J. Neyts, D. Schols, M. Cools, J. Balzarini, and E. De Clercq. 1993. Inhibitory activity of S-adenosylhomocysteine hydrolase inhibitors against human cytomegalovirus replication. Antiviral Res. 21:197-216.
165. Snoeck, R., G. Andrei, M. Gérard, A. Silverman, A. Hedderman, J. Balzarini, C. Sadzot-Delvaux, G. Tricot, N. Clumeck, and E. De Clercq. 1994. Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18:570-578.
166. Snoeck, R., M. Gérard, C. Sadzot-Delvaux, G. Andrei, J. Balzarini, D. Reymen, N. Ahadi, J. M. De Bruyn, J. Piette, B. Rentier, N. Clumeck, and E. De Clercq. 1994. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient. J. Med. Virol. 42:338-347.
167. Snoeck, R., M. Van Ranst, G. Andrei, E. De Clercq, S. De Wit, M. Poncin, and N. Clumeck. 1995. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. N. Engl. J. Med. 333: 943-944.
168. Snoeck, R., W. Wellens, C. Desloovere, M. Van Ranst, E. De Clercq, and L. Feenstra. 1996. Treatment of severe recurrent laryngeal papillomatosis by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir). Abstracts of the 9th International Conference on Antiviral Research. Antiviral Res. 30:A25.
169. Soike, K. F., J.-L. Huang, J.-Y. Zhang, R. Bohm, M. J. M. Hitchcock, and J. C. Martin. 1991. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (S-HPMPC) on simian varicella infection in monkeys. Antiviral Res. 16:17-28.
170. Starrett, J. E., Jr., D. R. Tortolani, J. Russell, M. J. M. Hitchcock, V. Whiterock, J. C. Martin, and M. M. Mansuri. 1994. Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adeine (PMEA). J. Med. Chem. 37:1857-1864.
171. Staszewksi, S., F. E. Massari, A. Kober, R. Gohler, S. Durr, K. W. Anderson, C. L. Schneider, J. A. Waterbury, K. K. Bakshi, V. I. Taylor, C. S. Hildebrand, C. Kreisl, B. Hoffstedt, W. A. Schleif, H. von Bliesen, H. Rubsamen-Waigmann, G. B. Calandra, J. L. Ryan, W. Stille, E. A. Emini, and V. W. Byrnes. 1995. Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor. J. Infect. Dis. 171:1159-1165.
172. Staszewski, S., V. Miller, A. Kober, R. Colebunders, B. Vandercam, J. Delescluse, N. Clumeck, F. Van Wanzeele, M. De Brabander, J. De Créé, M. Moeremans, K. Andries, C. Boucher, P. Stoffels, P. A. J. Janssen, and Members of the Loviride Collaborative Study Group. 1996. Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther. 1:42-50.
173. Staszewski, S., V. Miller, S. Rehmet, T. Stark, J. De Créé, M. De Brabander, M. Peeters, K. Andries, M. Moeremans, M. De Raeymaeker, G. Pearce, R. Van Den Broeck, W. Verbiest, and P. Stoffels. 1996. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 10:F1-F7.
174. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. J. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243:369-387.
175. Thormar, H., J. Balzarini, A. Holý, J. Jindrich, I. Rosenberg, Z. Debyser, J. Desmyter, and E. De Clercq. 1993. Inhibition of visna virus replication by 2′,3′-dideoxynucleosides and acyclic nucleoside phosphonate analogs. Antimicrob. Agents Chemother. 37:2540-2544.
176. Thormar, H., G. Georgsson, P. A. Pálsson, J. Balzarini, L. Naesens, S. Torsteinsdóttir, and E. De Clercq. 1995. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs. Proc. Natl. Acad. Sci. USA 92:3283-3287.
177. Tricot, G., E. De Clercq, M. A. Boogaerts, and R. L. Verwilghen. 1986. Oral bromo-vinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial. J. Med. Virol. 18:11-20.
178. mne infection in macaques. J. Med. Primatol. 23:175-183.
179. Tsai, C.-C., K. E. Follis, A. Sabo, R. F. Grant, C. Bartz, R. E. Nolte, R. E. Benveniste, and N. Bischofberger. 1994. Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J. Infect. Dis. 169:260-266.
180. Tsai, C.-C., K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199.
181. Vahlenkamp, T. W., A. De Ronde, J. Balzarini, L. Naesens, E. De Clercq, M. J. T. van Eijk, M. C. Horzinek, and H. F. Egberink. 1995. (R)-9-(2-Phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob. Agents Chemother. 39: 746-749.
182. 18O. Van Cutsem, E., R. Snoeck, M. Van Ranst, P. Fiten, G. Opdenakker, K. Geboes, J. Janssens, P. Rutgeerts, G. Vantrappen, and E. De Clercq. 1995. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl-)cytosine. J. Med. Virol. 45:230-235.
183. Vasudevachari, M. B., C. Battista, H. C. Lane, M. C. Psallidopoulos, B. Zhao, J. Cook, J. R. Palmer, D. L. Romero, W. G. Tarpley, and N. P. Salzman. 1992. Prevention of the spread of HIV-1 infection with non-nucleoside reverse transcriptase inhibitors. Virology 190:269-277.
184. Vere Hodge, R. A. 1993. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. 4:67-84.
185. Votruba, I., and A. Holý. 1980. Inhibition of S-adenosyl-L-homocysteine hydrolase by the aliphatic nucleoside analogue 9-(S)-(2,3-dihydroxypropyl)adenine. Collect. Czech. Chem. Commun. 45:3039-3044.
186. Wainberg, M. A., W. C. Drosopoulos, H. Salomon, M. Hsu, G. Borkow, M. A. Parniak, Z. Gu, Q. Song, J. Manne, S. Islam, G. Castriota, and V. R. Prasad. 1996. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271:1282-1285.
187. Walker, R. T. 1997. 4′-Thio-2′-deoxyribonucleosides, their chemistry and biological properties, p. 203-237. In P. H. Bentley and P. J. O'Hanlon (ed.), Anti-infectives. Recent advances in chemistry and structure-activity relationships. The Royal Society of Chemistry, Cambridge, United Kingdom.
188. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
189. Whittington, R., and R. N. Brogden. 1992. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 44:656-683.
190. Wigerinck, P., C. Pannecouque, R. Snoeck, P. Claes, E. De Clercq, and P. Herdewijn. 1991. 5-(5-Bromothien-2-yl)-2′-deoxyuridine and 5-(5-chlorothien-2-yl)-2′-deoxyuridine are equipotent to (E)-5-(2-bromovinyl)-2′-deoxyuridine in the inhibition of herpes simplex virus type I replication. J. Med. Chem. 34:2383-2389.
191. Wildiers, J., and E. De Clercq. 1984. Oral (E)-5-(2-bromovinyl)-2′-deoxyuridine treatment of severe herpes zoster in cancer patients. Eur. J. Cancer Clin. Oncol. 20:471-476.
192. Wutzler, P., E. De Clercq, K. Wutke, and I. Färber. 1995. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J. Med. Virol. 46:252-257.
193. Xiong, X. F., J. L. Smith, and M. S. Chen. 1995. The consequence of incorporation of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine by human cytomegalovirus DNA polymerase on DNA elongation. Abstracts of the 8th International Conference on Antiviral Research. Antiviral Res. 26:A321.
194. Xiong, X., J. L. Smith, C. Kim, E.-S. Huang, and M. S. Chen. 1996. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 51:1563-1567.